Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2019

View Archived Issues

Metastasizing cells create their own hypoxia

For proinflammatory antibody, too much of a bad thing is a good thing

Phase III results for V-212 inactivated varicella zoster virus vaccine in patients with malignancies

Novo Nordisk initiates phase I study of NNC0385-0434 for hypercholesterolemia

Recruitment ongoing in first-in-human trial of GB-1275

Velabs Therapeutics and Chiome Bioscience enter into a screening cooperation

Discovery and preclinical identification of novel mutant EGFR allosteric inhibitor JBJ-04-125-02

Celgene identifies CELMoD compounds for treating relapsed and refractory multiple myeloma

Merck & Co. describes heme-displacing inhibitors of IDO-1 with enhanced target engagement

Alpine Androsciences presents new androgen receptor antagonists

Aptinyx discovers NMDA receptor modulators

New TYK2 inhibitors disclosed by Nimbus Lakshmi

Foshan Ionova Biotherapeutics, Shenzhen Ionova Life Science patent PTGER4 antagonists

Vanderbilt University presents new muscarinic M4 receptor antagonists

2,3,6-Trisubstituted pyridine-containing M4 PAM shows selectivity and preclinical efficacy

Discovery of pyridinylimidazoles as brain-penetrant dual kinase inhibitors

Spider silk and iron oxide nanoparticles show promise for theranostic cancer applications

Immunicum reports phase II data on ilixadencel with sunitinib in metastatic renal cell carcinoma

European Commission approves Tecentriq for TNBC

Acurx completes multiple-ascending-dose phase I study of ACX-362E for C. difficile infection

Phase III TULIP 2 trial of anifrolumab in SLE meets primary endpoint

Amyndas opens phase IIa study of AMY-101 in periodontal inflammation